Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Mar 05, 2021 12:25pm
97 Views
Post# 32728881

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Maybe partnerships are coming soon

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Maybe partnerships are coming soonOther than the Water Tower Research thing, I have not seen anything that indicates any change in strategy on the IR front. And that one effort clearly will not be sufficient. So, I hope more change is coming. The BOD surely must know they have to get that fixed. 

scarlet1967 wrote: My problem is TH never participated in the rally , they came out with NASH hiv followed by many encouraging preclinical oncology results followed by new skillful CEO followed by general NASH followed by record breaking sales and FDA's letters study may proceed for both programs etc .yet they are following the pack loosing "market valuation" which never gained any traction during the bull market despite all the catalysts/progresses. They have achieved many milestones and failed so far on one milestone which is selling the company to the market.
Other companies have produced  less good results but managed to get credit for the little things they have done which is the opposite scenario where TH has so far done.
They need to understand regardless where you are in your process you need to promote it because otherwise other companies will run you over, rub your audience and leave you with left overs.


juniper88 wrote:
Bucknelly21 wrote: Well wino there's the sub three you were worried about....


The TSX Venture index is down over 6% today, similar to yesterday. 

So, companies like TH are down...




<< Previous
Bullboard Posts
Next >>